These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21865716)

  • 1. Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy.
    Okamoto Y; Fujikawa A; Kurosaki M; Yamasaki K; Sakurai D; Horiguchi S; Nakayama T
    Adv Otorhinolaryngol; 2011; 72():149-52. PubMed ID: 21865716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer.
    Kurosaki M; Horiguchi S; Yamasaki K; Uchida Y; Motohashi S; Nakayama T; Sugimoto A; Okamoto Y
    Cancer Immunol Immunother; 2011 Feb; 60(2):207-15. PubMed ID: 20978887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
    Uchida T; Horiguchi S; Tanaka Y; Yamamoto H; Kunii N; Motohashi S; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Immunol Immunother; 2008 Mar; 57(3):337-45. PubMed ID: 17690880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
    Kunii N; Horiguchi S; Motohashi S; Yamamoto H; Ueno N; Yamamoto S; Sakurai D; Taniguchi M; Nakayama T; Okamoto Y
    Cancer Sci; 2009 Jun; 100(6):1092-8. PubMed ID: 19302288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
    Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y
    Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Migration of tumor antigen-pulsed dendritic cells after mucosal administration in the human upper respiratory tract.
    Horiguchi S; Matsuoka T; Okamoto Y; Sakurai D; Kobayashi K; Chazono H; Hanazawa T; Tanaka Y
    J Clin Immunol; 2007 Nov; 27(6):598-604. PubMed ID: 17597385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Translational research in patients with lung cancer--clinical application of NKT cell immunotherapy].
    Motohashi S
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):550-3. PubMed ID: 17431340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.
    Nagato K; Motohashi S; Ishibashi F; Okita K; Yamasaki K; Moriya Y; Hoshino H; Yoshida S; Hanaoka H; Fujii S; Taniguchi M; Yoshino I; Nakayama T
    J Clin Immunol; 2012 Oct; 32(5):1071-81. PubMed ID: 22534863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T
    Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cancer Immunotherapy Using Allogeneic NKT Cells].
    Aoki T; Motohashi S
    Gan To Kagaku Ryoho; 2023 May; 50(5):584-588. PubMed ID: 37218316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cells induce CD4
    Ihara F; Sakurai D; Takami M; Kamata T; Kunii N; Yamasaki K; Iinuma T; Nakayama T; Motohashi S; Okamoto Y
    Cancer Immunol Immunother; 2019 Dec; 68(12):1935-1947. PubMed ID: 31641795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
    Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
    Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
    Moy JD; Moskovitz JM; Ferris RL
    Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
    Schuler PJ; Doescher JC; Laban S; Hoffmann TK
    HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
    Rozera C; Cappellini GA; D'Agostino G; Santodonato L; Castiello L; Urbani F; Macchia I; Aricò E; Casorelli I; Sestili P; Montefiore E; Monque D; Carlei D; Napolitano M; Rizza P; Moschella F; Buccione C; Belli R; Proietti E; Pavan A; Marchetti P; Belardelli F; Capone I
    J Transl Med; 2015 May; 13():139. PubMed ID: 25933939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.
    Horinaka A; Sakurai D; Ihara F; Makita Y; Kunii N; Motohashi S; Nakayama T; Okamoto Y
    Cancer Sci; 2016 Mar; 107(3):207-16. PubMed ID: 26679292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer.
    Ishibashi F; Sakairi Y; Iwata T; Moriya Y; Mizobuchi T; Hoshino H; Yoshida S; Hanaoka H; Yoshino I; Motohashi S
    Clin Immunol; 2020 Jun; 215():108457. PubMed ID: 32387537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.
    Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A
    Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
    Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
    Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond.
    Höchst B; Knolle PA
    ORL J Otorhinolaryngol Relat Spec; 2017; 79(1-2):24-33. PubMed ID: 28231588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.